Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry P Erba

Showing results (21-30 of 123) with videos related to

Pageof 13
Sort By:
Expert Opinion on Therapeutic Targets|January 12, 2011
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancerMeng Wang, Bruno C Medeiros, Harry P Erba, et al.
Leukemia|October 14, 2018
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studiesMegan Othus, Mikkael A Sekeres, Sucha Nand, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 13, 2019
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOMLauren E Merz, Anthony J Perissinotti, Bernard L Marini, et al.
Haematologica|July 14, 2022
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial dataMegan Othus, Guillermo Garcia-Manero, John E Godwin, et al.
Blood Cancer Journal|May 3, 2025
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024Daniel J Olivieri, Alexis Berridge-Green, Megan Othus, et al.
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Leukemia|January 27, 2025
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, et al.
Leukemia & Lymphoma|September 1, 2011
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemiaDavid Claxton, Harry P Erba, Stefan Faderl, et al.
Clinical Trials (London, England)|January 16, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trialsAnna Moseley, Michael LeBlanc, Boris Freidlin, et al.
Leukemia|June 3, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203Michelle Y Zhang, Megan Othus, Kerry McMillen, et al.
Pageof 13

Showing results (21-30 of 123) with videos related to

Sort By:
Pageof 13
Expert Opinion on Therapeutic Targets|January 12, 2011
Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancerMeng Wang, Bruno C Medeiros, Harry P Erba, et al.
Leukemia|October 14, 2018
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studiesMegan Othus, Mikkael A Sekeres, Sucha Nand, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 13, 2019
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOMLauren E Merz, Anthony J Perissinotti, Bernard L Marini, et al.
Haematologica|July 14, 2022
Improved outcomes with "7+3" induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial dataMegan Othus, Guillermo Garcia-Manero, John E Godwin, et al.
Blood Cancer Journal|May 3, 2025
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024Daniel J Olivieri, Alexis Berridge-Green, Megan Othus, et al.
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Leukemia|January 27, 2025
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, et al.
Leukemia & Lymphoma|September 1, 2011
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemiaDavid Claxton, Harry P Erba, Stefan Faderl, et al.
Clinical Trials (London, England)|January 16, 2025
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trialsAnna Moseley, Michael LeBlanc, Boris Freidlin, et al.
Leukemia|June 3, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203Michelle Y Zhang, Megan Othus, Kerry McMillen, et al.
Pageof 13